Payment overview · 2025
General Payments
$401.60
21 reported records · 9 companies
Healthcare provider profile · identity verified
Randy Hankins, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAZLEHURST, MS · NPI 1235231606
Verified facts
What the public records show
CMS Open Payments records show Randy Hankins, MD received $401.60 in general payments during 2025 across 21 reported records.
Abbott Laboratories accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 450 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $101.40 | 25.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.35 | 18.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.49 | 16.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.60 | 13.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.59 | 9.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.51 | 5.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.84 | 4.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.29 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.53 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $401.60 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $101.40 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.35 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.49 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $55.60 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.95 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.88 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 305 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
182 | 50 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
284 | 56 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
450 | 96 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
305 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 959 | 245 |
| Gabapentin | Gabapentin | 836 | 186 |
| Pantoprazole Sodium | Pantoprazole Sodium | 791 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 142 |
| Metformin Hcl | Metformin Hcl | 575 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 147 |
| Furosemide | Furosemide | 556 | 128 |
| Omeprazole | Omeprazole | 530 | 124 |
| Alprazolam | Alprazolam | 495 | 85 |
| Potassium Chloride | Potassium Chloride | 458 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 454 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 95 |
| Jardiance | Empagliflozin | 450 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 397 | 130 |
| Meloxicam | Meloxicam | 379 | 98 |
| Eliquis | Apixaban | 364 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 361 | 85 |
| Losartan Potassium | Losartan Potassium | 349 | 81 |
| Tizanidine Hcl | Tizanidine Hcl | 349 | 98 |
| Zolpidem Tartrate | Zolpidem Tartrate | 340 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 72 |
| Ozempic | Semaglutide | 305 | 50 |
| Tramadol Hcl | Tramadol Hcl | 299 | 80 |
| Nifedipine Er | Nifedipine | 292 | 64 |
| Farxiga | Dapagliflozin Propanediol | 284 | 56 |
| Glimepiride | Glimepiride | 271 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 267 | 70 |
| Carvedilol | Carvedilol | 239 | 59 |
| Trazodone Hcl | Trazodone Hcl | 239 | 48 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 239 | 46 |
| Lisinopril | Lisinopril | 236 | 58 |
| Famotidine | Famotidine | 233 | 50 |
| Simvastatin | Simvastatin | 232 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 226 | 43 |
| Montelukast Sodium | Montelukast Sodium | 223 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 214 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 213 | 53 |
| Allopurinol | Allopurinol | 202 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 192 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 188 | 44 |
| Naproxen | Naproxen | 186 | 49 |
| Linzess | Linaclotide | 182 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 36 |
| Ezetimibe | Ezetimibe | 176 | 41 |
| Clonidine Hcl | Clonidine Hcl | 174 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 36 |
| Pregabalin | Pregabalin | 171 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 154 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 151 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 52 |
| Sertraline Hcl | Sertraline Hcl | 149 | 34 |
| Donepezil Hcl | Donepezil Hcl | 146 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 142 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 138 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 30 |
| Atenolol | Atenolol | 136 | 25 |
| Tresiba Flextouch U-200 | Insulin Degludec | 129 | 30 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 127 | 32 |
| Levofloxacin | Levofloxacin | 123 | 93 |
| Azithromycin | Azithromycin | 122 | 100 |
| Levetiracetam | Levetiracetam | 121 | 23 |
| Spironolactone | Spironolactone | 115 | 26 |
| Valsartan | Valsartan | 115 | 34 |
| Januvia | Sitagliptin Phosphate | 114 | 17 |
| Ibuprofen | Ibuprofen | 113 | 34 |
| Meclizine Hcl | Meclizine Hcl | 112 | 33 |
| Temazepam | Temazepam | 110 | 21 |
| Fluconazole | Fluconazole | 108 | 50 |
| Clonazepam | Clonazepam | 106 | 17 |
| Lorazepam | Lorazepam | 103 | 23 |
| Buspirone Hcl | Buspirone Hcl | 101 | 19 |
| Xarelto | Rivaroxaban | 100 | 13 |
| Mirtazapine | Mirtazapine | 99 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | 23 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 91 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 67 |
| Colchicine | Colchicine | 87 | 34 |
| Trulicity | Dulaglutide | 86 | 17 |
| Bupropion Xl | Bupropion Hcl | 84 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 49 |
| Verapamil Er | Verapamil Hcl | 80 | 12 |
| Amoxicillin | Amoxicillin | 79 | 46 |
| Memantine Hcl | Memantine Hcl | 79 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 79 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 33 |
| Symbicort | Budesonide/Formoterol Fumarate | 76 | 15 |
| Myrbetriq | Mirabegron | 74 | 15 |
| Ondansetron Odt | Ondansetron | 74 | 32 |
| Prednisone | Prednisone | 73 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 17 |
| Ketoconazole | Ketoconazole | 68 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 23 |
| Entresto | Sacubitril/Valsartan | 65 | 14 |
| Mounjaro | Tirzepatide | 65 | 14 |
| Novolog Flexpen | Insulin Aspart | 65 | 23 |
| Cefuroxime | Cefuroxime Axetil | 64 | 51 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | suppressed |
| Aripiprazole | Aripiprazole | 57 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 14 |
| Benazepril Hcl | Benazepril Hcl | 55 | 15 |
| Metformin Hcl Er | Metformin Hcl | 54 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 14 |
| Mupirocin | Mupirocin | 53 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 13 |
| Celecoxib | Celecoxib | 52 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 52 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 11 |
| Trulance | Plecanatide | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 36 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Fenofibrate | Fenofibrate | 50 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | 11 |
| Methylprednisolone | Methylprednisolone | 50 | 43 |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Lactulose | Lactulose | 49 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 47 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Rexulti | Brexpiprazole | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Latanoprost | Latanoprost | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 36 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 17 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Mitigare | Colchicine | 31 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 22 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 11 |
| Dexamethasone | Dexamethasone | 25 | 24 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Indomethacin | Indomethacin | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | 20 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | 20 |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Azathioprine | Azathioprine | 24 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Metronidazole | Metronidazole | 22 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | 11 |
| Azelastine Hcl | Azelastine Hcl | 21 | 11 |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Glipizide | Glipizide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Victoza 2-Pak | Liraglutide | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.60 · 21 records | Abbott Laboratories | BREZTRI, CAPLYTA, ENTRESTO, FREESTYLE LIBRE, Kerendia, Korlym, LEQVIO, MOUNJARO, Ozempic, Rybelsus, VRAYLAR, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error